

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934  
(Amendment No. 2)\*

**CRYO CELL INTERNATIONAL INC.**

---

(Name of Issuer)

COMMON STOCK, par value \$0.01 per share  
(Title of Class of Securities)

---

228895108  
(CUSIP Number)

---

David Wilson, Davis Wright Tremaine LLP  
1201 Third Avenue, Suite 2200, Seattle, WA 98101  
(206) 757-8274

---

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

April 21, 2009  
(Date of Event Which Requires Filing of this Statement)

---

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

**SCHEDULE 13D**

CUSIP No. 228895108

<b>1</b>	NAME OF REPORTING PERSONS. I.R.S. Identification Nos. of above persons (entities only).  KI YONG CHOI	
<b>2</b>	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
<b>3</b>	SEC USE ONLY	
<b>4</b>	SOURCE OF FUNDS (SEE INSTRUCTIONS)  PF	
<b>5</b>	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)  <input type="checkbox"/>	
<b>6</b>	CITIZENSHIP OR PLACE OF ORGANIZATION  United States	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	<b>7</b>	SOLE VOTING POWER  2,136,929 (1)
	<b>8</b>	SHARED VOTING POWER  0
	<b>9</b>	SOLE DISPOSITIVE POWER  2,136,929 (1)
	<b>10</b>	SHARED DISPOSITIVE POWER  0
<b>11</b>	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  2,136,929 (1)	
<b>12</b>	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  <input type="checkbox"/>	
<b>13</b>	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  18.19%	
<b>14</b>	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  IN	

(1) 233,472 of the shares are held by Ki Yong Choi and Laura Choi, as trustees UAD 7/27/01 FBO Choi Family Living Trust, and the balance of the shares are held in the name of the reporting person.

This Amendment No. 2 to Schedule 13D is filed with respect to the Common Stock of CryoCell International, Inc. to amend the Schedule 13D filed by Reporting Person on July 26, 2007.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

The Reporting Person purchased 314,280 shares of Common Stock of Issuer in private sales between November 2008 and April 2009. The total purchase price was \$232,711.20 and Reporting Person utilized personal funds to complete each purchase. The source of the personal funds were cash distributions received by the Reporting Person from Cathedral Hill Associates, Inc. No funds were borrowed for the purchase.

ITEM 4. PURPOSE OF TRANSACTION

The Reporting Person has acquired the shares of Common Stock of Issuer for investment purposes and is a member of the Board of Directors of Issuer. Depending on market conditions, continuing evaluation of the business and prospects of the Issuer and other factors, the Reporting Person may dispose of or acquire additional shares of the Common Stock or other securities of Issuer or pursue strategic transactions as opportunities arise.

Except as set forth above, the Reporting Person has no present plans or intentions which would result in or relate to any of the transactions described in the instructions to Item 4.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

(a) The Reporting Person is the record holder of 1,903,457 shares of Common Stock of the Issuer and through the Ki Yong Choi and Laura Choi as Trustees UAD 7/27/01 FBO Choi Family Living Trust is the record holder of 233,472 shares of Common Stock of the Issuer, representing in the aggregate approximately 18.19% of the issued and outstanding Common Stock, based on the 11,750,543 shares of Common Stock issued and outstanding as of April 14, 2009 as reported on the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2009.

(b) The Reporting Person has sole voting and dispositive power of the 2,136,929 shares of Common Stock of Issuer.

(c) The Reporting Person has effected the following transactions in Issuer's Common Stock during the past 60 days:

<u>Date</u>	<u>Shares Purchased</u>	<u>Price per Share</u>
April 21, 2009	270,173	\$ 0.75
April 22, 2009	29,827	\$ 0.75

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, any securities beneficially owned by the Reporting Person.

(e) Not applicable.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: April 29, 2009

KI YONG CHOI

/s/ Ki Yong Choi

---